nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—DRD3—telencephalic ventricle—malignant glioma	0.0277	0.0779	CbGeAlD
L-DOPA—DDC—telencephalic ventricle—malignant glioma	0.027	0.0759	CbGeAlD
L-DOPA—DDC—pineal body—malignant glioma	0.0234	0.0658	CbGeAlD
L-DOPA—DRD1—telencephalic ventricle—malignant glioma	0.0198	0.0557	CbGeAlD
L-DOPA—PSIP1—embryo—malignant glioma	0.014	0.0393	CbGeAlD
L-DOPA—PSIP1—brainstem—malignant glioma	0.0128	0.036	CbGeAlD
L-DOPA—PSIP1—retina—malignant glioma	0.0124	0.0347	CbGeAlD
L-DOPA—DRD2—telencephalic ventricle—malignant glioma	0.0117	0.0329	CbGeAlD
L-DOPA—PSIP1—telencephalon—malignant glioma	0.0114	0.032	CbGeAlD
L-DOPA—PSIP1—medulla oblongata—malignant glioma	0.00893	0.0251	CbGeAlD
L-DOPA—PSIP1—midbrain—malignant glioma	0.00816	0.0229	CbGeAlD
L-DOPA—DDC—embryo—malignant glioma	0.00797	0.0224	CbGeAlD
L-DOPA—PSIP1—spinal cord—malignant glioma	0.00796	0.0224	CbGeAlD
L-DOPA—SLC7A8—telencephalon—malignant glioma	0.00749	0.0211	CbGeAlD
L-DOPA—DDC—brainstem—malignant glioma	0.0073	0.0205	CbGeAlD
L-DOPA—DDC—telencephalon—malignant glioma	0.00648	0.0182	CbGeAlD
L-DOPA—PSIP1—central nervous system—malignant glioma	0.00646	0.0182	CbGeAlD
L-DOPA—PSIP1—cerebellum—malignant glioma	0.00631	0.0177	CbGeAlD
L-DOPA—SLC7A5—retina—malignant glioma	0.00631	0.0177	CbGeAlD
L-DOPA—Hypokinesia—Carmustine—malignant glioma	0.00629	0.0253	CcSEcCtD
L-DOPA—DRD5—telencephalon—malignant glioma	0.00623	0.0175	CbGeAlD
L-DOPA—SLC7A5—telencephalon—malignant glioma	0.0058	0.0163	CbGeAlD
L-DOPA—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00545	0.0219	CcSEcCtD
L-DOPA—DRD1—brainstem—malignant glioma	0.00537	0.0151	CbGeAlD
L-DOPA—Coagulopathy—Temozolomide—malignant glioma	0.00527	0.0212	CcSEcCtD
L-DOPA—Memory impairment—Temozolomide—malignant glioma	0.00523	0.021	CcSEcCtD
L-DOPA—PSIP1—brain—malignant glioma	0.00513	0.0144	CbGeAlD
L-DOPA—DRD1—telencephalon—malignant glioma	0.00476	0.0134	CbGeAlD
L-DOPA—DDC—midbrain—malignant glioma	0.00465	0.0131	CbGeAlD
L-DOPA—SLC7A5—medulla oblongata—malignant glioma	0.00456	0.0128	CbGeAlD
L-DOPA—Gait disturbance—Carmustine—malignant glioma	0.00435	0.0175	CcSEcCtD
L-DOPA—DRD4—brain—malignant glioma	0.00427	0.012	CbGeAlD
L-DOPA—SLC7A8—central nervous system—malignant glioma	0.00426	0.012	CbGeAlD
L-DOPA—Gait disturbance—Temozolomide—malignant glioma	0.0042	0.0169	CcSEcCtD
L-DOPA—SLC7A5—midbrain—malignant glioma	0.00417	0.0117	CbGeAlD
L-DOPA—SLC7A8—cerebellum—malignant glioma	0.00416	0.0117	CbGeAlD
L-DOPA—Musculoskeletal pain—Temozolomide—malignant glioma	0.00415	0.0167	CcSEcCtD
L-DOPA—Urinary incontinence—Carmustine—malignant glioma	0.0041	0.0165	CcSEcCtD
L-DOPA—SLC7A5—spinal cord—malignant glioma	0.00407	0.0114	CbGeAlD
L-DOPA—Urinary incontinence—Temozolomide—malignant glioma	0.00396	0.0159	CcSEcCtD
L-DOPA—DRD3—central nervous system—malignant glioma	0.00378	0.0106	CbGeAlD
L-DOPA—DDC—central nervous system—malignant glioma	0.00368	0.0104	CbGeAlD
L-DOPA—Phlebitis—Carmustine—malignant glioma	0.00358	0.0144	CcSEcCtD
L-DOPA—DRD5—central nervous system—malignant glioma	0.00354	0.00996	CbGeAlD
L-DOPA—DRD1—midbrain—malignant glioma	0.00342	0.00961	CbGeAlD
L-DOPA—SLC7A8—brain—malignant glioma	0.00338	0.0095	CbGeAlD
L-DOPA—Vascular purpura—Temozolomide—malignant glioma	0.00333	0.0134	CcSEcCtD
L-DOPA—SLC7A5—central nervous system—malignant glioma	0.0033	0.00928	CbGeAlD
L-DOPA—SLC7A5—cerebellum—malignant glioma	0.00322	0.00907	CbGeAlD
L-DOPA—Hot flush—Temozolomide—malignant glioma	0.00318	0.0128	CcSEcCtD
L-DOPA—DRD2—brainstem—malignant glioma	0.00317	0.00891	CbGeAlD
L-DOPA—Menopausal symptoms—Temozolomide—malignant glioma	0.00316	0.0127	CcSEcCtD
L-DOPA—Purpura—Temozolomide—malignant glioma	0.00309	0.0124	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.00308	0.0124	CcSEcCtD
L-DOPA—Diplopia—Carmustine—malignant glioma	0.00308	0.0124	CcSEcCtD
L-DOPA—DRD2—retina—malignant glioma	0.00306	0.0086	CbGeAlD
L-DOPA—DRD3—brain—malignant glioma	0.003	0.00844	CbGeAlD
L-DOPA—Diplopia—Temozolomide—malignant glioma	0.00298	0.012	CcSEcCtD
L-DOPA—DDC—brain—malignant glioma	0.00292	0.00822	CbGeAlD
L-DOPA—Ataxia—Carmustine—malignant glioma	0.0029	0.0117	CcSEcCtD
L-DOPA—DRD2—telencephalon—malignant glioma	0.00281	0.00791	CbGeAlD
L-DOPA—DRD5—brain—malignant glioma	0.00281	0.00791	CbGeAlD
L-DOPA—Ataxia—Temozolomide—malignant glioma	0.0028	0.0113	CcSEcCtD
L-DOPA—DRD1—central nervous system—malignant glioma	0.00271	0.00761	CbGeAlD
L-DOPA—Dysphagia—Carmustine—malignant glioma	0.00266	0.0107	CcSEcCtD
L-DOPA—SLC7A5—brain—malignant glioma	0.00262	0.00736	CbGeAlD
L-DOPA—Dysphagia—Temozolomide—malignant glioma	0.00257	0.0104	CcSEcCtD
L-DOPA—Sweating increased—Temozolomide—malignant glioma	0.00251	0.0101	CcSEcCtD
L-DOPA—SLC16A10—cerebellum—malignant glioma	0.00247	0.00694	CbGeAlD
L-DOPA—Mesalazine—PPARG—malignant glioma	0.00241	0.212	CrCbGaD
L-DOPA—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00239	0.00963	CcSEcCtD
L-DOPA—Pollakiuria—Temozolomide—malignant glioma	0.00238	0.00957	CcSEcCtD
L-DOPA—Depression—Carmustine—malignant glioma	0.00237	0.00953	CcSEcCtD
L-DOPA—Weight increased—Temozolomide—malignant glioma	0.00234	0.00943	CcSEcCtD
L-DOPA—Weight decreased—Temozolomide—malignant glioma	0.00233	0.00937	CcSEcCtD
L-DOPA—Neuropathy peripheral—Carmustine—malignant glioma	0.00233	0.00937	CcSEcCtD
L-DOPA—Urinary tract infection—Carmustine—malignant glioma	0.00231	0.00929	CcSEcCtD
L-DOPA—Depression—Temozolomide—malignant glioma	0.00229	0.00921	CcSEcCtD
L-DOPA—Aminosalicylic Acid—PTGS1—malignant glioma	0.00227	0.2	CrCbGaD
L-DOPA—Neuropathy peripheral—Temozolomide—malignant glioma	0.00225	0.00906	CcSEcCtD
L-DOPA—Urinary tract infection—Temozolomide—malignant glioma	0.00223	0.00898	CcSEcCtD
L-DOPA—DRD1—brain—malignant glioma	0.00215	0.00604	CbGeAlD
L-DOPA—Haemoglobin—Carmustine—malignant glioma	0.00214	0.00863	CcSEcCtD
L-DOPA—Haemorrhage—Carmustine—malignant glioma	0.00213	0.00858	CcSEcCtD
L-DOPA—Hypoaesthesia—Carmustine—malignant glioma	0.00212	0.00854	CcSEcCtD
L-DOPA—Hallucination—Carmustine—malignant glioma	0.00212	0.00854	CcSEcCtD
L-DOPA—Haemoglobin—Temozolomide—malignant glioma	0.00207	0.00834	CcSEcCtD
L-DOPA—Haemorrhage—Temozolomide—malignant glioma	0.00206	0.00829	CcSEcCtD
L-DOPA—Hypoaesthesia—Temozolomide—malignant glioma	0.00205	0.00825	CcSEcCtD
L-DOPA—Hallucination—Temozolomide—malignant glioma	0.00205	0.00825	CcSEcCtD
L-DOPA—Urinary tract disorder—Temozolomide—malignant glioma	0.00203	0.00819	CcSEcCtD
L-DOPA—DRD2—midbrain—malignant glioma	0.00202	0.00568	CbGeAlD
L-DOPA—Urethral disorder—Temozolomide—malignant glioma	0.00202	0.00813	CcSEcCtD
L-DOPA—Flushing—Carmustine—malignant glioma	0.00198	0.00796	CcSEcCtD
L-DOPA—Flushing—Temozolomide—malignant glioma	0.00191	0.0077	CcSEcCtD
L-DOPA—Arrhythmia—Carmustine—malignant glioma	0.0019	0.00767	CcSEcCtD
L-DOPA—CYP2D6—brainstem—malignant glioma	0.0019	0.00535	CbGeAlD
L-DOPA—Alopecia—Carmustine—malignant glioma	0.00188	0.00758	CcSEcCtD
L-DOPA—Mental disorder—Carmustine—malignant glioma	0.00187	0.00752	CcSEcCtD
L-DOPA—Alopecia—Temozolomide—malignant glioma	0.00182	0.00733	CcSEcCtD
L-DOPA—Mental disorder—Temozolomide—malignant glioma	0.00181	0.00727	CcSEcCtD
L-DOPA—Back pain—Carmustine—malignant glioma	0.0018	0.00723	CcSEcCtD
L-DOPA—Mesalazine—PTGS1—malignant glioma	0.00178	0.157	CrCbGaD
L-DOPA—Dysgeusia—Temozolomide—malignant glioma	0.00176	0.00707	CcSEcCtD
L-DOPA—Vision blurred—Carmustine—malignant glioma	0.00175	0.00704	CcSEcCtD
L-DOPA—Tremor—Carmustine—malignant glioma	0.00174	0.007	CcSEcCtD
L-DOPA—Back pain—Temozolomide—malignant glioma	0.00174	0.00698	CcSEcCtD
L-DOPA—Anaemia—Carmustine—malignant glioma	0.00172	0.0069	CcSEcCtD
L-DOPA—Agitation—Carmustine—malignant glioma	0.00171	0.00687	CcSEcCtD
L-DOPA—Vision blurred—Temozolomide—malignant glioma	0.00169	0.0068	CcSEcCtD
L-DOPA—CYP2D6—telencephalon—malignant glioma	0.00169	0.00475	CbGeAlD
L-DOPA—Tremor—Temozolomide—malignant glioma	0.00168	0.00676	CcSEcCtD
L-DOPA—Ill-defined disorder—Temozolomide—malignant glioma	0.00166	0.0067	CcSEcCtD
L-DOPA—Leukopenia—Carmustine—malignant glioma	0.00166	0.00669	CcSEcCtD
L-DOPA—Anaemia—Temozolomide—malignant glioma	0.00166	0.00667	CcSEcCtD
L-DOPA—Agitation—Temozolomide—malignant glioma	0.00165	0.00663	CcSEcCtD
L-DOPA—Angioedema—Temozolomide—malignant glioma	0.00164	0.0066	CcSEcCtD
L-DOPA—Malaise—Temozolomide—malignant glioma	0.00162	0.00651	CcSEcCtD
L-DOPA—Convulsion—Carmustine—malignant glioma	0.00161	0.00647	CcSEcCtD
L-DOPA—Leukopenia—Temozolomide—malignant glioma	0.00161	0.00646	CcSEcCtD
L-DOPA—Hypertension—Carmustine—malignant glioma	0.0016	0.00645	CcSEcCtD
L-DOPA—DRD2—central nervous system—malignant glioma	0.0016	0.0045	CbGeAlD
L-DOPA—Palpitations—Temozolomide—malignant glioma	0.00159	0.00638	CcSEcCtD
L-DOPA—Chest pain—Carmustine—malignant glioma	0.00158	0.00636	CcSEcCtD
L-DOPA—Anxiety—Carmustine—malignant glioma	0.00157	0.00634	CcSEcCtD
L-DOPA—Cough—Temozolomide—malignant glioma	0.00157	0.0063	CcSEcCtD
L-DOPA—DRD2—cerebellum—malignant glioma	0.00156	0.00439	CbGeAlD
L-DOPA—Convulsion—Temozolomide—malignant glioma	0.00155	0.00625	CcSEcCtD
L-DOPA—Hypertension—Temozolomide—malignant glioma	0.00155	0.00623	CcSEcCtD
L-DOPA—Confusional state—Carmustine—malignant glioma	0.00153	0.00615	CcSEcCtD
L-DOPA—Anxiety—Temozolomide—malignant glioma	0.00152	0.00612	CcSEcCtD
L-DOPA—Oedema—Carmustine—malignant glioma	0.00151	0.0061	CcSEcCtD
L-DOPA—Discomfort—Temozolomide—malignant glioma	0.00151	0.00607	CcSEcCtD
L-DOPA—Dry mouth—Temozolomide—malignant glioma	0.00149	0.00601	CcSEcCtD
L-DOPA—Thrombocytopenia—Carmustine—malignant glioma	0.00148	0.00597	CcSEcCtD
L-DOPA—Confusional state—Temozolomide—malignant glioma	0.00148	0.00594	CcSEcCtD
L-DOPA—Oedema—Temozolomide—malignant glioma	0.00146	0.00589	CcSEcCtD
L-DOPA—Anorexia—Carmustine—malignant glioma	0.00144	0.00581	CcSEcCtD
L-DOPA—Thrombocytopenia—Temozolomide—malignant glioma	0.00143	0.00577	CcSEcCtD
L-DOPA—Hypotension—Carmustine—malignant glioma	0.00142	0.0057	CcSEcCtD
L-DOPA—Hyperhidrosis—Temozolomide—malignant glioma	0.00142	0.0057	CcSEcCtD
L-DOPA—Anorexia—Temozolomide—malignant glioma	0.0014	0.00562	CcSEcCtD
L-DOPA—Insomnia—Carmustine—malignant glioma	0.00137	0.00551	CcSEcCtD
L-DOPA—Dopamine—SLC6A3—malignant glioma	0.00136	0.12	CrCbGaD
L-DOPA—Paraesthesia—Carmustine—malignant glioma	0.00136	0.00547	CcSEcCtD
L-DOPA—Dyspnoea—Carmustine—malignant glioma	0.00135	0.00544	CcSEcCtD
L-DOPA—Somnolence—Carmustine—malignant glioma	0.00135	0.00542	CcSEcCtD
L-DOPA—Insomnia—Temozolomide—malignant glioma	0.00132	0.00533	CcSEcCtD
L-DOPA—Decreased appetite—Carmustine—malignant glioma	0.00132	0.0053	CcSEcCtD
L-DOPA—Paraesthesia—Temozolomide—malignant glioma	0.00131	0.00529	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Carmustine—malignant glioma	0.00131	0.00526	CcSEcCtD
L-DOPA—Dyspnoea—Temozolomide—malignant glioma	0.00131	0.00525	CcSEcCtD
L-DOPA—Somnolence—Temozolomide—malignant glioma	0.0013	0.00524	CcSEcCtD
L-DOPA—Aminosalicylic Acid—PTGS2—malignant glioma	0.0013	0.114	CrCbGaD
L-DOPA—Pain—Carmustine—malignant glioma	0.0013	0.00521	CcSEcCtD
L-DOPA—Constipation—Carmustine—malignant glioma	0.0013	0.00521	CcSEcCtD
L-DOPA—Dyspepsia—Temozolomide—malignant glioma	0.00129	0.00519	CcSEcCtD
L-DOPA—Decreased appetite—Temozolomide—malignant glioma	0.00127	0.00512	CcSEcCtD
L-DOPA—DRD2—brain—malignant glioma	0.00127	0.00357	CbGeAlD
L-DOPA—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00126	0.00509	CcSEcCtD
L-DOPA—Fatigue—Temozolomide—malignant glioma	0.00126	0.00508	CcSEcCtD
L-DOPA—Pain—Temozolomide—malignant glioma	0.00125	0.00504	CcSEcCtD
L-DOPA—Constipation—Temozolomide—malignant glioma	0.00125	0.00504	CcSEcCtD
L-DOPA—Feeling abnormal—Carmustine—malignant glioma	0.00125	0.00502	CcSEcCtD
L-DOPA—Gastrointestinal pain—Carmustine—malignant glioma	0.00124	0.00499	CcSEcCtD
L-DOPA—Epinephrine—TNF—malignant glioma	0.00124	0.109	CrCbGaD
L-DOPA—Feeling abnormal—Temozolomide—malignant glioma	0.00121	0.00486	CcSEcCtD
L-DOPA—Abdominal pain—Carmustine—malignant glioma	0.0012	0.00482	CcSEcCtD
L-DOPA—Gastrointestinal pain—Temozolomide—malignant glioma	0.0012	0.00482	CcSEcCtD
L-DOPA—Urticaria—Temozolomide—malignant glioma	0.00116	0.00468	CcSEcCtD
L-DOPA—Abdominal pain—Temozolomide—malignant glioma	0.00116	0.00466	CcSEcCtD
L-DOPA—Hypersensitivity—Carmustine—malignant glioma	0.00112	0.00449	CcSEcCtD
L-DOPA—Asthenia—Carmustine—malignant glioma	0.00109	0.00437	CcSEcCtD
L-DOPA—Hypersensitivity—Temozolomide—malignant glioma	0.00108	0.00434	CcSEcCtD
L-DOPA—Asthenia—Temozolomide—malignant glioma	0.00105	0.00423	CcSEcCtD
L-DOPA—Diarrhoea—Carmustine—malignant glioma	0.00104	0.00417	CcSEcCtD
L-DOPA—Pruritus—Temozolomide—malignant glioma	0.00104	0.00417	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—malignant glioma	0.00102	0.0895	CrCbGaD
L-DOPA—Dizziness—Carmustine—malignant glioma	0.001	0.00403	CcSEcCtD
L-DOPA—Diarrhoea—Temozolomide—malignant glioma	0.001	0.00403	CcSEcCtD
L-DOPA—Dizziness—Temozolomide—malignant glioma	0.000968	0.0039	CcSEcCtD
L-DOPA—Vomiting—Carmustine—malignant glioma	0.000963	0.00388	CcSEcCtD
L-DOPA—CYP2D6—central nervous system—malignant glioma	0.000961	0.0027	CbGeAlD
L-DOPA—Rash—Carmustine—malignant glioma	0.000955	0.00384	CcSEcCtD
L-DOPA—Dermatitis—Carmustine—malignant glioma	0.000954	0.00384	CcSEcCtD
L-DOPA—Headache—Carmustine—malignant glioma	0.000949	0.00382	CcSEcCtD
L-DOPA—CYP2D6—cerebellum—malignant glioma	0.000939	0.00264	CbGeAlD
L-DOPA—Vomiting—Temozolomide—malignant glioma	0.000931	0.00375	CcSEcCtD
L-DOPA—Rash—Temozolomide—malignant glioma	0.000923	0.00371	CcSEcCtD
L-DOPA—Dermatitis—Temozolomide—malignant glioma	0.000922	0.00371	CcSEcCtD
L-DOPA—Headache—Temozolomide—malignant glioma	0.000917	0.00369	CcSEcCtD
L-DOPA—Nausea—Carmustine—malignant glioma	0.0009	0.00362	CcSEcCtD
L-DOPA—Nausea—Temozolomide—malignant glioma	0.00087	0.0035	CcSEcCtD
L-DOPA—CYP2D6—brain—malignant glioma	0.000763	0.00214	CbGeAlD
L-DOPA—DRD2—Signaling by GPCR—F2—malignant glioma	4.78e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NCOR1—malignant glioma	4.75e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—RAF1—malignant glioma	4.75e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2—malignant glioma	4.73e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CD—malignant glioma	4.73e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TERT—malignant glioma	4.72e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2—malignant glioma	4.69e-05	0.000122	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—RAF1—malignant glioma	4.69e-05	0.000122	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PIK3CA—malignant glioma	4.69e-05	0.000122	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CB—malignant glioma	4.64e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—KRAS—malignant glioma	4.63e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2—malignant glioma	4.63e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PDGFRA—malignant glioma	4.61e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT2—malignant glioma	4.61e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PDGFB—malignant glioma	4.6e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGFR1—malignant glioma	4.58e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CB—malignant glioma	4.58e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CG—malignant glioma	4.57e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PDGFRA—malignant glioma	4.55e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—FGF2—malignant glioma	4.53e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HIF1A—malignant glioma	4.51e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTPN11—malignant glioma	4.49e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SPP1—malignant glioma	4.48e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH2—malignant glioma	4.46e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—malignant glioma	4.46e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CD—malignant glioma	4.43e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SPP1—malignant glioma	4.42e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—malignant glioma	4.4e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KNG1—malignant glioma	4.37e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CAV1—malignant glioma	4.36e-05	0.000113	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KDR—malignant glioma	4.31e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2—malignant glioma	4.26e-05	0.000111	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PIK3CA—malignant glioma	4.26e-05	0.000111	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TERT—malignant glioma	4.25e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MDM2—malignant glioma	4.24e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RAF1—malignant glioma	4.23e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2—malignant glioma	4.2e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TERT—malignant glioma	4.19e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT2—malignant glioma	4.18e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB2—malignant glioma	4.18e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NTRK1—malignant glioma	4.16e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—F2—malignant glioma	4.15e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FN1—malignant glioma	4.15e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PDGFB—malignant glioma	4.14e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CB—malignant glioma	4.13e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGFR1—malignant glioma	4.12e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—BAD—malignant glioma	4.1e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PDGFB—malignant glioma	4.09e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGFR1—malignant glioma	4.07e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOTCH1—malignant glioma	4.06e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HIF1A—malignant glioma	4.06e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CD—malignant glioma	4.02e-05	0.000105	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HIF1A—malignant glioma	4.01e-05	0.000104	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTT1—malignant glioma	3.98e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CD80—malignant glioma	3.98e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APC—malignant glioma	3.97e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CG—malignant glioma	3.97e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—malignant glioma	3.96e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGF—malignant glioma	3.93e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CAV1—malignant glioma	3.93e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTPN11—malignant glioma	3.9e-05	0.000102	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KDR—malignant glioma	3.88e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CAV1—malignant glioma	3.88e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP3—malignant glioma	3.87e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CB—malignant glioma	3.86e-05	0.0001	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CDKN2B—malignant glioma	3.83e-05	9.97e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KDR—malignant glioma	3.83e-05	9.97e-05	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—malignant glioma	3.83e-05	9.96e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PIK3CA—malignant glioma	3.83e-05	9.96e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—malignant glioma	3.79e-05	9.87e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2—malignant glioma	3.79e-05	9.85e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—F2—malignant glioma	3.74e-05	9.72e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FN1—malignant glioma	3.74e-05	9.72e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—BRAF—malignant glioma	3.74e-05	9.72e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS1—malignant glioma	3.73e-05	9.71e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTK2—malignant glioma	3.72e-05	9.69e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—malignant glioma	3.71e-05	9.64e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BAD—malignant glioma	3.69e-05	9.61e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—F2—malignant glioma	3.69e-05	9.59e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FN1—malignant glioma	3.69e-05	9.59e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HES1—malignant glioma	3.66e-05	9.52e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOTCH1—malignant glioma	3.66e-05	9.51e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BAD—malignant glioma	3.64e-05	9.48e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NCOR1—malignant glioma	3.64e-05	9.46e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT2—malignant glioma	3.64e-05	9.46e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—EGFR—malignant glioma	3.62e-05	9.42e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOTCH1—malignant glioma	3.61e-05	9.39e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RAF1—malignant glioma	3.59e-05	9.33e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—malignant glioma	3.59e-05	9.33e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CD80—malignant glioma	3.58e-05	9.32e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APC—malignant glioma	3.58e-05	9.3e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CG—malignant glioma	3.58e-05	9.3e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTEN—malignant glioma	3.57e-05	9.27e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2—malignant glioma	3.54e-05	9.22e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGF—malignant glioma	3.54e-05	9.2e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CD80—malignant glioma	3.54e-05	9.2e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APC—malignant glioma	3.53e-05	9.18e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CG—malignant glioma	3.53e-05	9.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTPN11—malignant glioma	3.51e-05	9.14e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CB—malignant glioma	3.5e-05	9.11e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CD—malignant glioma	3.49e-05	9.09e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGF—malignant glioma	3.49e-05	9.07e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFRA—malignant glioma	3.48e-05	9.06e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—malignant glioma	3.48e-05	9.05e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BCHE—malignant glioma	3.47e-05	9.03e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTPN11—malignant glioma	3.47e-05	9.02e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PIK3CA—malignant glioma	3.46e-05	9e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC5A5—malignant glioma	3.43e-05	8.92e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KRAS—malignant glioma	3.42e-05	8.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SPP1—malignant glioma	3.38e-05	8.8e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—malignant glioma	3.37e-05	8.76e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—BRAF—malignant glioma	3.36e-05	8.75e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—FGF2—malignant glioma	3.34e-05	8.7e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—BRAF—malignant glioma	3.32e-05	8.63e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT2—malignant glioma	3.27e-05	8.51e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—EGFR—malignant glioma	3.26e-05	8.48e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT2—malignant glioma	3.23e-05	8.4e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—malignant glioma	3.22e-05	8.38e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2—malignant glioma	3.22e-05	8.37e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—EGFR—malignant glioma	3.22e-05	8.36e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TERT—malignant glioma	3.21e-05	8.34e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—malignant glioma	3.19e-05	8.29e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CD—malignant glioma	3.14e-05	8.18e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PIK3CA—malignant glioma	3.14e-05	8.17e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MDM2—malignant glioma	3.13e-05	8.14e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFB—malignant glioma	3.13e-05	8.14e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—malignant glioma	3.13e-05	8.13e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RAF1—malignant glioma	3.12e-05	8.11e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PIK3CA—malignant glioma	3.12e-05	8.1e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGFR1—malignant glioma	3.11e-05	8.1e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CD—malignant glioma	3.1e-05	8.07e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—malignant glioma	3.09e-05	8.03e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KRAS—malignant glioma	3.08e-05	8.01e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PIK3CA—malignant glioma	3.07e-05	7.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HIF1A—malignant glioma	3.07e-05	7.97e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CB—malignant glioma	3.04e-05	7.92e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KRAS—malignant glioma	3.04e-05	7.9e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—FGF2—malignant glioma	3.01e-05	7.83e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—FGF2—malignant glioma	2.97e-05	7.73e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CAV1—malignant glioma	2.97e-05	7.71e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—malignant glioma	2.96e-05	7.71e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KDR—malignant glioma	2.93e-05	7.63e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—malignant glioma	2.93e-05	7.61e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—EGFR—malignant glioma	2.9e-05	7.54e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PIK3CA—malignant glioma	2.83e-05	7.36e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—malignant glioma	2.83e-05	7.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—F2—malignant glioma	2.82e-05	7.34e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FN1—malignant glioma	2.82e-05	7.34e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MDM2—malignant glioma	2.82e-05	7.33e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RAF1—malignant glioma	2.81e-05	7.3e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—malignant glioma	2.8e-05	7.28e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2—malignant glioma	2.8e-05	7.27e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PIK3CA—malignant glioma	2.79e-05	7.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BAD—malignant glioma	2.79e-05	7.25e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MDM2—malignant glioma	2.78e-05	7.23e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—malignant glioma	2.78e-05	7.22e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RAF1—malignant glioma	2.77e-05	7.21e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOTCH1—malignant glioma	2.76e-05	7.18e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTP1—malignant glioma	2.76e-05	7.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CB—malignant glioma	2.74e-05	7.13e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—malignant glioma	2.74e-05	7.13e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KRAS—malignant glioma	2.74e-05	7.12e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CD80—malignant glioma	2.71e-05	7.04e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CB—malignant glioma	2.7e-05	7.03e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APC—malignant glioma	2.7e-05	7.02e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CG—malignant glioma	2.7e-05	7.02e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAT—malignant glioma	2.69e-05	6.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGF—malignant glioma	2.67e-05	6.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTPN11—malignant glioma	2.65e-05	6.9e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—malignant glioma	2.65e-05	6.88e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—malignant glioma	2.63e-05	6.85e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTEN—malignant glioma	2.63e-05	6.84e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—malignant glioma	2.6e-05	6.76e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—malignant glioma	2.57e-05	6.68e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—malignant glioma	2.54e-05	6.62e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—BRAF—malignant glioma	2.54e-05	6.6e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NCOR1—malignant glioma	2.54e-05	6.6e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—malignant glioma	2.52e-05	6.56e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2—malignant glioma	2.52e-05	6.55e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CA—malignant glioma	2.52e-05	6.54e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—malignant glioma	2.51e-05	6.53e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—malignant glioma	2.49e-05	6.47e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2—malignant glioma	2.48e-05	6.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT2—malignant glioma	2.47e-05	6.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—EGFR—malignant glioma	2.46e-05	6.4e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—malignant glioma	2.43e-05	6.33e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—malignant glioma	2.38e-05	6.2e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—malignant glioma	2.38e-05	6.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CD—malignant glioma	2.37e-05	6.18e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTEN—malignant glioma	2.37e-05	6.16e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—malignant glioma	2.35e-05	6.12e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CA—malignant glioma	2.35e-05	6.12e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—malignant glioma	2.35e-05	6.11e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTEN—malignant glioma	2.34e-05	6.08e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KRAS—malignant glioma	2.32e-05	6.05e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—malignant glioma	2.31e-05	6.01e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—malignant glioma	2.28e-05	5.93e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—FGF2—malignant glioma	2.27e-05	5.91e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—malignant glioma	2.19e-05	5.69e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—malignant glioma	2.14e-05	5.56e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EGFR—malignant glioma	2.14e-05	5.56e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CA—malignant glioma	2.14e-05	5.55e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MDM2—malignant glioma	2.13e-05	5.53e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RAF1—malignant glioma	2.12e-05	5.51e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—malignant glioma	2.12e-05	5.51e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—malignant glioma	2.11e-05	5.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—malignant glioma	2.1e-05	5.45e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—malignant glioma	2.09e-05	5.44e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CB—malignant glioma	2.07e-05	5.38e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAV1—malignant glioma	2.07e-05	5.38e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—malignant glioma	2.05e-05	5.34e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KRAS—malignant glioma	2.02e-05	5.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—malignant glioma	1.99e-05	5.17e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—malignant glioma	1.97e-05	5.12e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—malignant glioma	1.94e-05	5.05e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EGFR—malignant glioma	1.93e-05	5.01e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—malignant glioma	1.92e-05	5e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—malignant glioma	1.9e-05	4.95e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2—malignant glioma	1.9e-05	4.94e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EGFR—malignant glioma	1.9e-05	4.94e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CG—malignant glioma	1.88e-05	4.9e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CA—malignant glioma	1.86e-05	4.83e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KRAS—malignant glioma	1.82e-05	4.73e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—malignant glioma	1.82e-05	4.73e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—malignant glioma	1.8e-05	4.68e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—malignant glioma	1.8e-05	4.67e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KRAS—malignant glioma	1.79e-05	4.67e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTEN—malignant glioma	1.79e-05	4.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—malignant glioma	1.74e-05	4.54e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CA—malignant glioma	1.67e-05	4.35e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CD—malignant glioma	1.66e-05	4.31e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CA—malignant glioma	1.65e-05	4.29e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—malignant glioma	1.62e-05	4.2e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—malignant glioma	1.62e-05	4.2e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—malignant glioma	1.6e-05	4.16e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—malignant glioma	1.6e-05	4.15e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—malignant glioma	1.52e-05	3.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—malignant glioma	1.49e-05	3.87e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EGFR—malignant glioma	1.45e-05	3.78e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CB—malignant glioma	1.44e-05	3.76e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—malignant glioma	1.43e-05	3.72e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KRAS—malignant glioma	1.37e-05	3.57e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—malignant glioma	1.37e-05	3.55e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—malignant glioma	1.35e-05	3.5e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CA—malignant glioma	1.26e-05	3.28e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTEN—malignant glioma	1.25e-05	3.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—malignant glioma	1.22e-05	3.17e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—malignant glioma	1.03e-05	2.68e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CA—malignant glioma	8.8e-06	2.29e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—malignant glioma	7.19e-06	1.87e-05	CbGpPWpGaD
